VEGF mitigates bisphosphonate-induced apoptosis and differentiation inhibition of MC3T3-E1 cells
Yao Duan1, Heija Li2, Xiaohong Dong3
1Department of Second Dental Center, Peking University School and Hospital of Stomatology, Beijing 100101, P.R. China.
Abstract:
The present study aimed to investigate whether VEGF was involved in bisphosphonate (BP)-induced apoptosis and differentiation of osteoblasts. Murine MC3T3-E1 osteoblasts were stimulated with zoledronic acid (ZA) for 7 days. VEGF mRNA and protein expression levels were determined via reverse transcription-quantitative PCR and western blot analysis, respectively. Cell viability was evaluated using Cell Counting Kit-8 assay. In addition, the cell apoptotic rate and the expression levels of apoptosis-related proteins were measured using a TUNEL staining kit and western blot analysis, respectively. To evaluate mineralization, cells were stained with alizarin red, while the secretion levels of alkaline phosphatase (ALP) were measured using the corresponding assay kit. Finally, the expression levels of differentiation-related proteins and proteins of the Nod-like receptor family pyrin domain-containing 3 (NLRP3)/caspase 1/gasdermin D (GSDMD) pyroptosis pathway were measured by western blot analysis. VEGF expression level was notably decreased in ZA-stimulated MC3T3-E1 cells. However, the viability of these cells was enhanced following VEGF addition. Furthermore, VEGF attenuated apoptosis, promoted mineralization and increased ALP activity in ZA-stimulated MC3T3-E1 cells. The ZA-mediated decrease in the protein expression of the osteogenic genes osteopontin, osteocalcin and runt-related transcription factor 2 was restored after MC3T3-E1 cell treatment with 10 ng/ml VEGF. The present study demonstrated that VEGF could attenuate BP-induced apoptosis and differentiation of MC3T3 cells by regulating the NLRP3/caspase 1/GSDMD pathway.
Insights
Vascular Endothelial Growth Factor (VEGF) protects osteoblasts from bisphosphonate-induced apoptosis and differentiation. VEGF addition enhanced cell viability, mineralization, and alkaline phosphatase activity, while reducing apoptosis in zoledronic acid-treated cells.
Area of Science:
- Molecular Biology
- Cell Biology
- Biochemistry
Background:
- Bisphosphonates (BPs) are commonly used to treat bone diseases.
- The effects of BPs on osteoblast apoptosis and differentiation require further investigation.
- Vascular Endothelial Growth Factor (VEGF) is a key regulator of angiogenesis and cellular processes.
Purpose of the Study:
- To investigate the role of VEGF in bisphosphonate (BP)-induced apoptosis and differentiation of osteoblasts.
- To elucidate the molecular mechanisms underlying VEGF's effects on osteoblasts treated with zoledronic acid (ZA).
Main Methods:
- Murine MC3T3-E1 osteoblasts were treated with zoledronic acid (ZA).
- VEGF expression, cell viability, apoptosis, mineralization, and alkaline phosphatase (ALP) activity were assessed.
- Western blot analysis was used to evaluate protein expression, including osteogenic genes and the NLRP3/caspase 1/GSDMD pathway.
Main Results:
- Zoledronic acid (ZA) treatment decreased VEGF expression in MC3T3-E1 cells.
- VEGF addition enhanced cell viability, promoted mineralization, and increased ALP activity in ZA-treated cells.
- VEGF attenuated ZA-induced apoptosis and restored the expression of osteogenic genes (osteopontin, osteocalcin, RUNX2).
Conclusions:
- VEGF plays a protective role against bisphosphonate-induced apoptosis and differentiation in osteoblasts.
- VEGF attenuates BP-induced apoptosis and differentiation by regulating the NLRP3/caspase 1/GSDMD pathway.
- VEGF may be a potential therapeutic target for managing bone-related disorders associated with bisphosphonate treatment.
Related Concept Videos
Regulation of Angiogenesis and Blood Supply
Mitogens and the Cell Cycle
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...


